ANAB Research and Charts

ANAB - AnaptysBio Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-07-11)

Last 26.20	Change ⇑ +0.11 (+0.42%)	Volume 338,683
	Open 25.94	High 26.69	Low 25.44

8EMA (Daily) 24.54	40EMA (Daily) 22.69	50EMA (Daily) 22.29	STO (Daily) 76.704	MACD Hist (Daily) 0.494
8EMA (Weekly) 23.265	40EMA (Weekly) 21.78	50EMA (Weekly) 22.01	STO (Weekly) 85.600	MACD Hist (Weekly) 1.442


Company Profile
AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.